Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors

Stopped early · Phase 1

Conditions studied: Advanced Cancer, Advanced Solid Tumors

In brief

The study is being conducted to determine the maximum tolerated dose, overall safety and tolerability profile, and pharmacokinetic profile of CP-751,871 and sunitinib when given in combination with advanced solid tumors.

Key facts

Study ID

NCT00729833

Run by

Pfizer

People needed

45

Starts

2008-09-01

Expected to finish

2013-04-01

Last updated by the study team

2014-06-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed advanced solid tumors relapsed or refractory to standard therapy or for whom no standard therapy exists.
• ECOG Performance Status of 0 or 1;
• Total IGF-1 level ≥100 ng/ml;
• ECOG Performance Status of 0 or 1
• Adequate bone marrow, renal, and hepatic function

You may not qualify if…

• Concurrent treatment with any antitumor agents with the exception of LHRH agnosits for prostate cancer patients
• Treatment with any other investigational therapy within 4 weeks prior to study treatment
• Major surgery within 4 weeks of study treatment
• Prior treatment that may increase the risk of cardiac complications
• Ongoing cardiac dysrhythmias of NCI CTCAE Grade 2 or greater
• Significant active cardiac disease, including hypertension that cannot be controlled by medications
• Greater than three (3) prior lines of cytotoxic therapy;
• Active infection
• Prior IGF-IR targeted therapy;

Where it is running

• Pfizer Investigational Site — Los Angeles, California, United States
• Pfizer Investigational Site — Santa Monica, California, United States
• Pfizer Investigational Site — Philadelphia, Pennsylvania, United States
• Pfizer Investigational Site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.